Merck says an injected version of its blockbuster infusion Keytruda is quicker and easier. But it stands to slow the adoption of cheaper competitors, increasing costs by billions of dollars.
Your daily dose of insights
Merck says an injected version of its blockbuster infusion Keytruda is quicker and easier. But it stands to slow the adoption of cheaper competitors, increasing costs by billions of dollars.